hVIVO is making a strategic move to solidify its position in early-stage clinical research with the €10 million acquisition of CRS Clinical Research Services Management GmbH. This deal secures two trial sites in Germany, expanding hVIVO’s capabilities in cardiometabolic, immunology, and complex PK/PD studies while strengthening its foothold in the European market.
The acquisition brings two key CRS units into hVIVO’s network—one in Mannheim, specialising in cardiometabolic and immunology trials, and another in Kiel, focusing on studies involving renal and hepatic impaired patients. These sites, which house a total of 120 beds, generated €19.9 million in revenue in 2023 and €18.6 million in 2022.
While CRS’ Berlin research facility will continue operating independently, it will remain hVIVO’s preferred partner for specialised trials, ensuring continued collaboration between the two firms.
hVIVO CEO Yamin “Mo” Khan emphasised the transformative potential of the deal, stating that it significantly strengthens and diversifies the business. The acquisition is expected to create new synergies, growth opportunities, and help drive hVIVO toward its ambitious target of £100 million in revenue by 2028.
The company anticipates that the acquisition will unlock cross-selling opportunities, benefiting both hVIVO and its sister company, Venn Life Sciences. By expanding its client base and revenue streams, the deal positions hVIVO for long-term, sustainable growth. Additionally, CRS will now be able to offer laboratory, biometry, and consulting services while enhancing its clinical, CMC, PK, and regulatory capabilities.
Looking ahead, hVIVO reaffirmed its 2025 revenue forecast of £73 million, attributing its growth trajectory to the CRS acquisition and recently secured contracts. The company expects an increase in average contract sizes across its service lines, further strengthening its financial outlook.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
